[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Taizhou Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":118},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,38,69,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100585482","establishment-and-clinical-application-of-breast-cancer-risk-prediction-model-based-on-traditional-chinese-medicine-four-diagnostic-instruments-and-ultrasound-100585482",false,"NCT06902935","Establishment and Clinical Application of Breast Cancer Risk Prediction Model Based on Traditional Chinese Medicine Four Diagnostic Instruments and Ultrasound","Inclusion Criteria:\n\n1. Female patients aged between 30 and 75.\n2. Patients who have a mass detected by US examination, need to undergo surgery or needle biopsy, and obtain a definite pathological result.\n3. Patients who have obtained complete identification results of tongue, pulse, face, and constitution through the traditional Chinese medicine four diagnostic instruments.\n\nExclusion Criteria:\n\n\\- 1. Patients with severe heart, liver, or kidney insufficiency, or other serious systemic diseases.\n\n2\\. Patients with a history of other malignant tumors. 3. Cases with poor - quality B - ultrasound images. 4. Cases with an unclear pathological diagnosis. 5. Patients with obvious lesions on the face, in the oral cavity, or on the tongue that may affect the measurement results.","FEMALE","30 Years","75 Years",{"count":19,"type":20},1500,"ESTIMATED","OBSERVATIONAL","Construct a breast cancer risk prediction model based on traditional Chinese medicine four diagnostic instruments and B-ultrasound images. Ensure that the key evaluation indicators of the model reach a high level through clinical verification, so as to contribute to accurate clinical diagnosis and treatment decision-making.",[24],"Breast Cancer Screening","NOT_YET_RECRUITING","2025-03-24",{"date":28,"type":29},"2025-03-30","ACTUAL",{"date":31,"type":20},"2025-04-26",{"date":33,"type":20},"2027-04-26",{"name":35,"class":36},"Taizhou Hospital","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100549998","phase-3-toripalimab-plus-anlotinib-for-the-maintenance-of-extensive-stage-small-cell-100549998","NCT06441344","Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell","First-line Etoposide Combined With Platinum-based Chemotherapy Followed by Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell Carcinoma - A Randomized, Controlled, Multicenter Phase III Clinical Study","SCLC","Inclusion Criteria:\n\n* Male or female aged ≥ 18 and\\\u003C80 years old.\n* The ECOG score is 0-1 points (including 0 and 1 points), and the expected survival period is not less than 3 months.\n* Confirmed as small cell lung cancer (SCLC) by histopathology or cytology and diagnosed as extensive after systemic evaluation.\n* I have not received first-line treatment for ES-SCLC systemic chemotherapy or immune checkpoint inhibitors in the past.\n* Limited stage SCLC progresses to extensive stage SCLC after receiving previous radiotherapy and chemotherapy aimed at cure,at least 6 months of no treatment period is required after the last radiotherapy and\u002For chemotherapy treatment.\n* Patients with previous active brain metastases have stabilized after treatment and do not require immediate or planned brain intervention during the study period Transfer for local treatment.\n* According to the criteria for evaluating the efficacy of solid tumors (RECIST v1.1), enrolled patients should have at least one tumor throughout their body The tumor lesion can meet the following requirements: it has not undergone local treatment such as radiotherapy in the past and is at baseline Can be accurately measured, with a baseline maximum diameter of ≥ 10mm (if it is a lymph node, a minimum diameter of ≥ 15mm is required).\n\nLesions that have previously received local treatment (radiotherapy or other treatments), if the treatment is completed for at least 6 months If disease progression occurs later, the lesion in the area that has undergone local treatment can be considered a measurable lesion.\n\n* Patients should have sufficient bone marrow reserve function and no liver, kidney, or coagulation dysfunction, and laboratory tests should be conducted\n* The value must meet the following conditions:\n\n  1. Absolute neutrophil count ≥ 1.5 × 109\u002FL, and white blood cell count ≥ 3 × 109\u002FL;\n  2. Platelet count ≥ 100 × 109\u002FL;\n  3. Hemoglobin ≥ 90g\u002FL;\n  4. Serum creatinine (Cr) ≤ 1.5 x Upper limit of normal (ULN) or creatinine clearance rate (CrCl) ≥ 50ml\u002Fmin (for patients with serum creatinine\\>1.5 x ULN);\n  5. If there is no confirmed liver metastasis, AST and ALT ≤ 2.5 × ULN; If there is confirmed liver metastasis, AST,ALT ≤ 5 × ULN;\n  6. If there is no confirmed liver metastasis, total bilirubin ≤ 1.5 × ULN; If there is confirmed liver metastasis or patients with syndrome (high indirect bilirubinemia), total bilirubin ≤ 3 x ULN;\n  7. If there is no confirmed liver metastasis, alkaline phosphatase (ALP) ≤ 2.5 x ULN or ≤ 5 x ULN (bone metastasis)\n  8. Albumin (ALB)\\>30g\u002Fdl;\n  9. 24-hour urine protein quantification\\\u003C1g (if urine protein ≥ 2+, additional 24-hour urine protein testing is required)\n  10. Serum lipase or amylase ≤ 1.5 x ULN or\\>1.5 x ULN (clinical or imaging diagnosis of pancreas)\n  11. International standardized ratio (INR) ≤ 1.5, and activated partial prothrombin time (APTT)≤ 1.5 x ULN.\n* Female subjects with reproductive ability have a negative blood pregnancy result within 7 days before starting the study treatment, and are willing to From the time of signing the informed consent form until the end of the last medication use, abstain from sexual activity or take medication for a period of 6 months medically recognized and efficient contraceptive measures (such as intrauterine devices, condoms, etc.), but the use of hormones is prohibited Using similar drugs for contraception; Male subjects are willing to take informed consent from the time of signing until the end of the last medication use Within the next 6 months, abstain from sexual activity or use medically recognized and effective contraceptive measures (such as condoms),and during this period, no sperm will be donated;.\n* The subjects are able to understand and voluntarily sign a written informed consent form (the informed consent form must be completed before conducting the study) Sign before any program specified in the plan.\n* Be able to voluntarily complete the research procedures and follow-up examinations according to the requirements of the research protocol.\n\nExclusion Criteria:\n\n* Mixed small cell lung cancer diagnosed by histology or cytology;\n* A history of severe allergic diseases, severe drug (including unmarketed investigational drugs) allergies, or known adverse reactions to this medication Allergy to any component of the investigational drug: presence of etoposide, platinum based drugs (carboplatin\u002Fcisplatin), or anlotinib.Individuals who are contraindicated to the use of anlotide or Toripalimab;\n* Previously received treatment with immune checkpoint agonists (such as CD137 agonists) or immune checkpoint inhibitors.Preparation therapy (such as single\u002Fdual antibodies against CTLA-4, PD-1, PD-L1, LAG3, etc.) or anti VEGF targeted drugs;\n* Previously received curative radiotherapy (excluding those who met the inclusion criteria of 5), or before receiving study treatment.Has undergone extensive palliative radiotherapy within 4 weeks, or plans to undergo chest radiotherapy during the study period\n* Need or plan to undergo elective surgical treatment during the trial period;\n* Received the following treatments or medications before starting the research treatment:\n\n  1. Received important organ surgery (excluding puncture) within 28 days before starting the study and treatment Inspection;\n  2. Received attenuated live vaccine within 28 days prior to starting treatment;\n  3. Have used intravenous broad-spectrum antibiotics for at least 7 days within 14 days before starting the study treatment;\n  4. Starting the study on systemic corticosteroids (prednisone\\>10) received within 14 days prior to treatment Mg\u002Fday or equivalent dose of similar drugs or other immunosuppressive treatments; Except for the following situations External: Treatment with local, ocular, intra-articular, intranasal, and inhaled corticosteroids; short Regular use of glucocorticoids for preventive treatment (such as preventing contrast agent allergies);\n  5. Received palliative radiotherapy for bone metastases within 14 days prior to starting the study treatment;\n* Currently, there is spinal cord compression or superior vena cava syndrome;\n* Currently, there are clear cases of interstitial lung disease or non infectious pneumonia, except for those caused by local radiotherapy;\n* There are brain metastases in the midbrain, pons, medulla oblongata, spinal cord, meninges, and meninges, or symptomatic large brain metastases Brain or cerebellar metastasis (such as manifested as cerebral edema and\u002For progressive growth); Central nervous system conversion\n\nIndividuals limited to the brain and cerebellum can participate in screening if they meet the following conditions:\n\na. Asymptomatic brain metastases (asymptomatic central nervous system progressive symptoms caused by brain metastases, also not necessary) Using corticosteroids or antiepileptic drugs for treatment; b. Symptoms stabilize for at least 2 weeks after radiotherapy for brain metastases, and corticosteroids or antiepileptic drugs are discontinued Drug discontinuation for at least 2 weeks;\n\n* Evidence of significant coagulation disorders or other significant bleeding risks:\n\n  1. History of intracranial hemorrhage or spinal cord hemorrhage;\n  2. Patients with tumor lesions invading large blood vessels and having a significant risk of bleeding;\n  3. Within the 6 months prior to the start of the study treatment, there have been incidents of thrombosis or embolism (asymptomatic and none) Except for intramuscular venous thrombosis that requires treatment, there is no absorption during follow-up examination, or significant vascular disease is present (For aortic aneurysm, aortic dissection, etc. that require surgical repair);\n  4. Clinically significant hemoptysis or tumor development for any reason within the first 3 months prior to starting the study treatment Blood;\n  5. Within 14 days prior to the start of the study, use anticoagulant therapy for therapeutic purposes (with low prophylactic use) Excluding molecular weight heparin;\n* Past or current active autoimmune diseases or immunodeficiency, including but not limited to severe muscle disease Weakness, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammation Sexually transmitted bowel disease, antiphospholipid antibody syndrome, Wegener's granulomatosis, Sj ö gren syndrome, Grimm Barr syndrome Li syndrome or multiple sclerosis; Except for: a Autoimmune related hypothyroidism Subjects with a history of withdrawal and currently taking thyroid replacement hormone; b. Stable status receiving insulin treatment 30% of subjects with type I diabetes.\n* Lesions limited to subjects with eczema, psoriasis, chronic simple lichen, and vitiligo on the skin (if diseased)\n\nWhen the damage has already affected parts or organs outside the skin (such as psoriasis, arthritis, etc.), it cannot be included in the group:\n\ni. Fever of unknown origin\\>38.5 ℃ (fever caused by tumor can be included in the group);\n\n* Within 6 months prior to starting the study of drug therapy, the following situations occurred:\n\n  1. Suffering from congestive heart failure, severe\u002Funstable angina, cerebrovascular accident, New York, USA Cardiac insufficiency classified by the Society of Cardiology (NYHA) as Grade II or above (including Grade II), Or other structural heart diseases that have been determined by researchers to be at high risk;\n  2. History of abdominal fistula, tracheoesophageal fistula, gastrointestinal perforation, or abdominal abscess;\n  3. There is uncontrollable tumor related pain, and if painkillers are needed, they should be stable during screening A prescribed pain relief treatment plan; Asymptomatic metastatic lesions, if further grown, may lead to Causing functional impairment or stubborn pain (such as epidural metastases that are currently unrelated to spinal cord compression), If appropriate, local treatment should be considered before screening;\n* Within the 5 years prior to starting the research on drug therapy, if there were other active malignant tumors, local treatment may be necessary Except for malignant tumors that have been treated and cured (such as basal cell or squamous cell carcinoma of the skin, superficial or non malignant) Invasive bladder cancer cancer, cervical carcinoma in situ, breast intraductal carcinoma in situ, thyroid papillary carcinoma);\n* Individuals who have received allogeneic hematopoietic stem cell transplantation or organ transplantation in the past;\n* Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS);\n* Syphilis antibody positive and active syphilis infection present;\n* Individuals with active pulmonary tuberculosis or a history of pulmonary tuberculosis infection that cannot be controlled after treatment;\n* 20 HBsAg or HBcAb positive, and HBV-DNA\\>2000 IU\u002FmL (for For patients with HBV DNA\\>500 IU\u002FmL, the subject must agree to at least 7 days prior to the start of the study drug Continuously receiving antiviral treatment other than interferon during the research period is necessary to participate in screening; HCV antibodies Positive and HCV-RNA higher than the lower limit of detection in the experimental center (if the center is unable to detect HCV) RNA, acceptable external hospital results, relevant reports should be provided);\n* Expected to receive any other form of anti-tumor drug treatment during the trial period;\n* Known to have a history of alcohol abuse, psychotropic substance abuse, or drug use;\n* Individuals with mental disorders or poor compliance;\n* Pregnant or lactating women\n* According to the judgment of the researchers, the basic condition of the subjects may increase their risk of receiving study drug treatment,Or confusion caused by the occurrence of toxic reactions and the explanation of AE;\n* Other researchers deemed it unsuitable to participate in this experiment;","ALL","18 Years","80 Years",{"count":50,"type":20},136,"INTERVENTIONAL",[53],"PHASE3","This is a randomized, open, multicenter Phase III clinical study. A total of 136 participants are planned to be enrolled and randomly assigned to either the experimental group (platinum+etoposide → toripalimab plus anlotinib) or the control group (platinum+etoposide+ toripalimab → toripalimab) in a 1:1 ratio. The primary efficacy measures include PFS, while secondary endpoints include OS, DOR, ORR, DCR, progression free survival at 6 and 12 months, overall survival at 12 and 18 months, health-related quality of life (FACT-L), safety, etc. And in the III clinical study, tissue samples were collected before treatment, and tumor tissue and blood samples were taken from some patients after 3 cycles of maintenance treatment and treatment progression for single-cell sequencing and transcriptome sequencing to verify the underlying mechanism research",[44,56],"Maintenance Treatment",[58,56,59,60],"ES-SCLC","Toripalimab","Anlotinib","2024-05-28",{"date":63,"type":29},"2024-06-04",{"date":65,"type":20},"2024-07-01",{"date":67,"type":20},"2030-05-01",{"name":35,"class":36},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":76,"targetDuration":4,"studyType":51,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100540677","phase-2-high-dose-furmonertinib-versus-osimertinib-in-advanced-egfrm-nsclc-patients-with-brain-metastases-100540677","NCT06319950","High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases","High-dose Furmonertinib Versus Osimertinib as First-line Treatment in Advanced EGFR Mutation-positive NSCLC Patients With Brain Metastases: a Multi-center, Randomized, Controlled, Prospective, Phase II Clinical Trial","Inclusion Criteria:\n\n* Male or female subjects aged \\>=18 and \\\u003C=80 years old.\n* Patients with histologically or cytologically confirmed NSCLC with adenocarcinoma or adenocarcinoma components predominant, and with central nervous system metastases (with measurable lesions).\n* The tissue or blood sample is determined to be EGFR positive (including rare EGFR mutations) by testing by a tertiary Class A hospital or a qualified testing institution, and the tissue submitted for testing cannot be from a tumor lesion that has been treated with radiation, but can be used for a new lesion after local treatment.\n* Patients who had not previously received systemic anti-tumor therapy for locally advanced or metastatic non-small cell lung cancer (patients who had received first-line chemotherapy but had not received TKIs could be enrolled). Patients who have undergone radical surgery, radical chemo-radiotherapy, or adjuvant therapy (chemotherapy, radiation) for early NSCLC may be enrolled if they later develop disease recurrence or metastasis.\n* Stable brain metastases that do not require local treatment of brain metastases either immediately or planned during the study period.\n* According to RECIST v1.1, enrolled patients should have at least one tumor lesion in all tumors that can meet the following requirements: they have not been treated with local therapy such as radiotherapy in the past, and can be accurately measured at baseline, and the longest diameter at baseline is ≥10mm (in the case of lymph nodes, the short diameter is ≥15mm). Lesions that have previously received local treatment (radiotherapy or other treatment) can only be measured if disease progression occurs more than 6 months after the end of treatment.\n* ECOG PS 0-1, and with no deterioration during the first 2 weeks of the study and expected survival time of no less than 3 months.\n* Patients should have sufficient bone marrow reserve function, and no liver, kidney, coagulation dysfunction, laboratory test values must meet the following conditions:\n\n  1. Absolute neutrophil count ≥ 1.5×109\u002FL, and white blood cell count ≥3×109\u002FL;\n  2. PLT ≥100×109\u002FL;\n  3. Hb ≥90g\u002FL;\n  4. Serum Cr ≤1.5×ULN and eGFR ≥50 mL\u002Fmin;\n  5. AST and ALT≤2.5×ULN (or AST and ALT≤5×ULN for patients with liver metastasis)\n  6. In the absence of proven liver metastasis, TB ≤1.5×ULN (or TB ≤3×ULN for patients with liver metastasis or Gilbert syndrome;\n  7. INR ≤1.5, and APTT ≤1.5×ULN.\n* Male patients and female patients of reproductive age should take adequate contraceptive measures within 3 months after signing the study informed consent to the last study drug treatment; In women of childbearing age, pregnancy test results are negative within 7 days before the first dose.\n* All previous treatment-related toxicities (except alopecia and grade 2 neurotoxicity associated with previous platinum chemotherapy) had been recovered (to ≤ grade 1) before first administration of the investigational drug.\n* The subject is able to understand and voluntarily sign a written informed consent (which must be signed prior to performing any procedure specified in the study protocol).\n* Be able to voluntarily complete the study procedures and follow-up examinations as required by the study protocol.\n\nExclusion Criteria:\n\n* Patients with the following treatments:\n\n  1. Previous use of any EGFR TKIs therapy;\n  2. Previously received systemic antitumor therapy (such as targeted therapy, biotherapy, immunotherapy, etc.) for advanced\u002Fmetastatic non-small cell lung cancer;\n  3. Standard chemotherapy within 28 days before the first administration of the study drug; The study received anti-tumor therapy with traditional Chinese medicine within 7 days before the first administration of the drug;\n  4. Previous WBRT; Had received \\>30% of bone marrow radiotherapy or extensive radiotherapy within 28 days prior to the first dose of the study drug; Local radiotherapy (e.g., thoracic and rib radiotherapy) or palliative radiotherapy for bone metastases within 7 days prior to initial administration of the study drug;\n  5. Uncontrolled pleuroperitoneal effusion and pericardial effusion;\n  6. Uncontrollable cancerous pain; Anesthetic painkillers did not reach a stable dose at the time of enrollment;\n  7. Study major surgery within 28 days before the first administration of the drug ( major surgery refers to grade 3 and grade 4 surgery in Measures for the Clinical Application of Medical Technology in China, on May 1, 2009 );\n  8. Has received a strong inducer or suppressor of CYP3A4 within 14 days prior to initial administration of the investigatory drug or requires continued treatment during the study period (including Chinese herbal medicine, see Appendix for a list of drugs);\n  9. Patients who are receiving and require continued treatment during the study with drugs known to prolong the QTc interval or that may cause tip torsion ventricular tachycardia (see Appendix for a list of drugs);\n  10. Participants who have participated in other clinical trials within 28 days prior to the first administration of the investigational drug (except non-interventional drug trials);\n* Patients with primary malignant brain tumors and unstable brain metastases. Definition of unstable brain metastases: Patients with CNS complications who require emergency neurosurgical treatment (such as surgery); Patients with an equivalent dose of dexamethasone or more than 5mg of glucocorticoids, mannitol or diuretics to control symptoms of brain metastases should be administered within 14 days prior to the first dose; The first study looked at patients who had received local radiotherapy or gamma knife treatment within 14 days prior to administration. Patients with meningeal metastasis were excluded.\n* Patients who have had or have a history of other malignancies within the past 5 years (except cured basal cell or squamous cell carcinoma of the skin, papillary carcinoma of the thyroid gland, carcinoma in situ of the cervix, and ductal carcinoma in situ of the breast).\n* The patient had symptoms of spinal cord compression caused by the tumor.\n* Clinically significant gastrointestinal dysfunction that may affect the intake, transport, or absorption of investigational drugs, such as inability to take oral drugs, difficult to control nausea or vomiting, a history of extensive gastrointestinal resection, Untreated recurrent diarrhea, atrophic gastritis (onset age less than 60 years), untreated stomach disease requiring long-term use of PPI acid suppressants, Crohn's disease, ulcerative colitis.\n* Cardiovascular and cerebrovascular diseases\u002Fsymptoms\u002Findications that meet any of the following conditions:\n\n  1. Average resting QTc≥470ms (corrected QT interval, calculated according to Fridericia's formula, see Appendix 18-9), the average QTc of 3 ECG intervals of more than 5 minutes, and the QT interval should be measured from the beginning of the QRS complex wave to the end of the T wave;\n  2. Any abnormalities in rhythm, conduction, or morphology of the clinically significant resting ECG, such as complete left bundle branch block, 2nd and 3rd degree heart block, PR interval \\> 250ms;\n  3. Any factors that increase the risk of prolonged QTc or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or sudden unexplained death in a first-degree relative under the age of 40-year-old, or any combination of medications known to prolong the QT interval;\n  4. LVEF \\\u003C50%;\n  5. Patients with a history of decreased myocardial contractility and related symptoms in the 6 months prior to study administration, such as chronic congestive heart failure, pulmonary edema, or decreased ejection fraction;\n  6. Patients with a history of acute and chronic cardiovascular and cerebrovascular disease and related symptoms within 6 months prior to study administration, such as myocardial infarction, severe or unstable angina pectoris, cerebral infarction, cerebral hemorrhage, or transient ischemic attack.\n* Persons infected with HIV, syphilis, HCV or HBV, meeting the following conditions:\n\n  1. HBs Ag positive and HBV DNA ≥2000cps\u002F mL (or 500IU\u002F mL);\n  2. Anti-HCV antibody and HCV RNA positive;\n  3. HIV antibody positive.\n* Prior or screening history of interstitial lung disease or ILD, or drug-induced ILD, or radiation pneumonia requiring hormone therapy, or any evidence of active ILD (such as acute onset or progressive pneumonia\u002Fpulmonary fibrosis at baseline), or pulmonary symptoms deemed unsuitable for inclusion by the investigator or risk factors deemed unsuitable for interstitial lung disease.\n* Had previously received allogeneic bone marrow transplantation.\n* Pregnant and lactating women.\n* The patient has any other disease or medical condition that is unstable or may affect their safety or study compliance, any serious or uncontrolled systemic disease, including autoimmune disease requiring corticosteroid therapy, uncontrolled hypertension (SBP ≥150 mmHg or DBP ≥95 mmHg), Uncontrolled diabetes, active bleeding, eye lesions, and other serious mental, neurological, cardiovascular, or respiratory diseases.\n* Known or suspected allergy to the investigational drug ingredient or its analogues.\n* The subjects were judged by the investigator to be unfit for this study.",{"count":77,"type":20},255,[79],"PHASE2","The investigators were to explore whether high-dose Furmonertinib, compared with osimertinib, could achieve longer survival in patients with EGFR-mutated NSCLC with CNS metastasis.",[82],"Lung Cancer, Nonsmall Cell",[84,85,86,87],"non-small cell lung cancer (NSCLC)","brain metastases","epidermal growth factor receptor (EGFR)","tyrosine kinase inhibitors (TKI)","2024-03-13",{"date":90,"type":29},"2024-03-20",{"date":92,"type":20},"2024-04-01",{"date":94,"type":20},"2026-12-30",{"name":35,"class":36},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":103,"targetDuration":4,"studyType":51,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":5},"100424961","phase-2-18f-fdg-petct-guided-reduced-dose-radiotherapy-for-nasopharyngeal-carcinoma-100424961","NCT04813705","18F-FDG PET\u002FCT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma","A Multicenter Phase II Study of 18F-FDG PET\u002FCT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Pathology confirmed nasopharyngeal squamous cell carcinoma.\n2. Stage I-IVA（8thAJCC\u002FUICC staging system).\n3. Aged 18-80 years.\n4. KPS≥70.\n5. Have measurable lesions on 18F-FDG PET\u002FCT before treatment.\n6. HGB≥90 g\u002FL，ANC≥1.5×109 \u002FL，PLT≥80×109 \u002FL.\n7. ALT,AST\\\u003C2.5 fold of ULN；TBIL\\\u003C2.0×ULN.\n8. CCR≥60ml\u002Fmin or Cr\\\u003C1.5×ULN.\n9. Signed informed consent.\n10. Have follow up condition.\n\nExclusion Criteria:\n\n1. Past malignancies history (except for stage I non-melanoma skin cancer or cervical carcinoma in situ).\n2. Age \\\u003C18 or \\>80years.\n3. Pregnancy or lactation.\n4. History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume).\n5. Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes.\n6. With sever infection and internal disease.\n7. Major organ dysfunction, such as decompensated cardiopulmonary, kidney, liver failure, cannot tolerate surgical treatment.",{"count":104,"type":20},93,[79],"The purpose of this study is to explore whether 18F-FDG PET\u002FCT guided reduced-dose radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (NPC) patients.",[108],"Nasopharyngeal Carcinoma","RECRUITING","2023-02-17",{"date":112,"type":29},"2023-02-21",{"date":114,"type":29},"2022-01-01",{"date":116,"type":20},"2029-06-30",{"name":35,"class":36},""]